LifeMine Therapeutics Announces $175 Million Series C Financing
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the completion of a $175 million Series C financing.
- LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the completion of a $175 million Series C financing.
- Proceeds from the financing will be used to advance LifeMines proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx.
- LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere.
- Headquartered in Cambridge, Mass., and with a second site at Gloucester Harbor, Mass., LifeMine has raised more than $295 million from leading life science investors.